CA
NZ
UK
AU
IND
US
…
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009; and Memorial Sloan Kettering Cancer Center for developing and commercializing MSK's WT1 peptide vaccine technology. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -26.86M | -30.88M | -37.34M | -41.30M | -20.94M |
| Net income | -26.86M | -30.88M | -37.34M | -40.65M | -20.70M |
| Selling general administrative | 12.25M | 12.42M | 13.86M | 12.58M | 11.32M |
| Gross profit | - | - | 0.00M | 0.90M | 7.40M |
| Ebit | - | -30.88M | -37.34M | -41.95M | -25.29M |
| Ebitda | -26.86M | 0.63M | 0.53M | -42.28M | -29.65M |
| Depreciation and amortization | - | 31.51M | 37.87M | -0.33M | -4.35M |
| Operating income | -28.27M | -31.51M | -37.87M | -41.95M | -25.29M |
| Other operating expenses | 28.27M | 31.51M | 37.87M | 42.95M | 32.89M |
| Interest expense | - | - | - | -0.65M | 4.36M |
| Tax provision | - | - | - | 0.00M | -0.24M |
| Interest income | 1.41M | 0.63M | 0.64M | 0.32M | 0.01M |
| Net interest income | 1.41M | 0.63M | 0.64M | 0.32M | 0.01M |
| Income tax expense | - | - | -37.87M | -0.65M | -0.24M |
| Total revenue | 0.00M | 0.00M | 0.00M | 1.00M | 7.60M |
| Total operating expenses | 28.27M | 31.51M | 37.87M | 42.85M | 32.69M |
| Cost of revenue | - | - | 0.00M | 0.10M | 0.20M |
| Total other income expense net | 1.41M | 0.63M | 0.53M | 0.65M | 4.36M |
| Net income from continuing ops | -26.86M | -30.88M | -38.33M | -41.30M | -20.70M |
| Net income applicable to common shares | - | - | - | -41.30M | -20.70M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 78.34M | 19.43M | 6.40M | 20.94M | 26.27M |
| Other current assets | 3.32M | 2.44M | 0.54M | 0.05M | 0.03M |
| Total liab | 7.47M | 9.97M | 14.38M | 16.09M | 5.93M |
| Total stockholder equity | 70.87M | 9.46M | -7.98M | 4.85M | 20.35M |
| Other current liab | 3.52M | 5.47M | 7.65M | 11.79M | 0.16M |
| Common stock | 0.01M | 0.01M | 0.00M | 0.00M | 0.00M |
| Capital stock | 0.01M | 0.01M | 0.00M | 0.00M | 0.00M |
| Retained earnings | -274.99M | -248.12M | -217.24M | -179.90M | -138.60M |
| Other liab | - | - | - | 0.00M | 0.34M |
| Good will | 1.91M | 1.91M | 1.91M | 1.91M | 1.91M |
| Other assets | - | -0.20M | 0.00M | 0.40M | 0.59M |
| Cash | 71.89M | 13.89M | 2.63M | 17.12M | 21.36M |
| Total current liabilities | 7.02M | 9.51M | 13.73M | 15.52M | 4.98M |
| Current deferred revenue | - | - | - | - | 2.48M |
| Net debt | -70.89M | -12.88M | -1.72M | -16.18M | -20.55M |
| Short term debt | 0.54M | 0.54M | 0.45M | 0.37M | 0.20M |
| Short long term debt total | 1.00M | 1.00M | 0.91M | 0.94M | 0.81M |
| Other stockholder equity | 345.84M | 257.58M | 209.26M | 184.75M | 158.95M |
| Property plant equipment | - | - | - | 0.87M | 0.72M |
| Total current assets | 75.21M | 16.33M | 3.17M | 17.76M | 23.04M |
| Net tangible assets | - | - | - | 2.94M | 18.43M |
| Accounts payable | 2.95M | 3.50M | 5.64M | 3.36M | 2.14M |
| Non currrent assets other | 0.26M | 0.47M | 0.28M | 0.40M | 0.59M |
| Non current assets total | 3.13M | 3.31M | 3.23M | 3.19M | 3.23M |
| Capital lease obligations | 1.00M | 1.00M | 0.91M | 0.94M | 0.81M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | - | 0.00M | -5.50M | -4.50M | - |
| Change to liabilities | - | - | - | 1.21M | -8.11M |
| Total cashflows from investing activities | - | - | -5.50M | -4.50M | -4.50M |
| Total cash from financing activities | 86.30M | 46.76M | 22.32M | 24.08M | 12.07M |
| Change to operating activities | - | - | - | 4.43M | 0.50M |
| Net income | -26.86M | -30.88M | -37.34M | -41.30M | -20.70M |
| Change in cash | 57.91M | 11.36M | -14.60M | -4.23M | -13.95M |
| Begin period cash flow | 13.99M | 2.63M | 17.23M | 21.45M | 35.40M |
| End period cash flow | 71.89M | 13.99M | 2.63M | 17.23M | 21.45M |
| Total cash from operating activities | -28.39M | -35.40M | -31.41M | -23.81M | -26.02M |
| Issuance of capital stock | 23.05M | 46.16M | 19.75M | 23.99M | 9.01M |
| Depreciation | - | - | - | - | 5.68M |
| Other cashflows from investing activities | - | - | -5.50M | - | - |
| Sale purchase of stock | - | - | -0.03M | - | - |
| Other cashflows from financing activities | -0.53M | 0.59M | 0.09M | 0.09M | 3.07M |
| Change to netincome | - | - | - | 11.85M | 2.29M |
| Capital expenditures | 0.00M | 0.00M | 5.50M | 4.50M | 0.00M |
| Change in working capital | -4.08M | -6.65M | 3.35M | 5.64M | -7.62M |
| Stock based compensation | 1.96M | 1.56M | 1.39M | 1.73M | 1.01M |
| Other non cash items | 0.60M | 0.56M | 1.20M | 10.12M | -4.16M |
| Free cash flow | -28.39M | -35.40M | -36.91M | -28.31M | -26.02M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| SLS Sellas Life Sciences Group Inc |
0.83 7.32% |
12.17 | - | - | 26.90 | 17.20 | 20.84 | -1.71 |
| NVO Novo Nordisk A/S |
-0.46 1.18% |
38.67 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
3.54 0.68% |
521.03 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
8.43 1.04% |
816.10 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
- -% |
790.15 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009; and Memorial Sloan Kettering Cancer Center for developing and commercializing MSK's WT1 peptide vaccine technology. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.
| Name | Title | Year Born |
|---|---|---|
| Dr. Angelos M. Stergiou M.D., ScD h.c. | Founder, Pres, CEO & Director | 1976 |
| Ms. Barbara A. Wood | Exec. VP, Gen. Counsel & Sec. | 1963 |
| Dr. Dragan Cicic M.D., MBA | Sr. VP of Clinical Devel. | 1963 |
| Mr. John Thomas Burns CPA | Sr. VP of Fin. & Chief Accounting Officer | 1985 |
| Mr. Robert M. Francomano | Sr. VP & Chief Commercial Officer | 1967 |
| Mr. Jörg W. Breitkopf | Head of Clinical Operations | NA |
| Dr. Angelos M. Stergiou M.D., ScD h.c. | Founder, President, CEO & Director | 1976 |
| Mr. John Thomas Burns CPA | Senior VP & CFO | 1985 |
| Ms. Stacy E. Yeung | VP, Associate General Counsel & Head of Compliance | NA |
| Dr. Dragan Cicic M.D., MBA | Senior Vice President of Clinical Development | 1963 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
+1.59%
Communication Services
+0.05%
Consumer Cyclical
+0.14%
Consumer Defensive
-0.43%
Energy
-0.03%
Financial Services
+0.19%
Financials
-0.35%
Healthcare
+1.05%
Industrials
+0.67%
Real Estate
-0.25%
Technology
+1.31%
Utilities
+0.32%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...